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1. Introduction 
Endoscopic retrograde cholangiopancreatography (ERCP) is an essential modality for the 
diagnosis and therapy of pancreatobiliary disease. However, complications of ERCP-related 
procedures are also common. Post-ERCP pancreatitis (PEP), the most common and 
potentially serious complication of ERCP-related procedures, occurs in 1 - 9% of all 
procedures (1-16). Moreover, the PEP rate increases to 10 - 40% in cases with risk factors (1-
16). In most cases, PEP is generally mild and requires only conservative treatment. 
However, substantial complications, occasionally fatal, can occur. Therefore, it is imperative 
to establish a strategy for preventing PEP based on medical, social, and economical 
circumstances. The prevention of PEP, according to various studies, is presently based on 
the elucidation of its underlying mechanisms, the identification of its risk factors, the 
administration of pharmacological drugs, and endoscopic procedures such as pancreatic 
stenting.  
2. Mechanisms of post-ERCP pancreatitis  
Various mechanisms of PEP have been suggested (1-25), which include obstruction of the 
outflow of pancreatic juice due to papillary edema or spasm of the sphincter of Oddi after 
ERCP procedures, chemical injury due to the injection of contrast material or leakage of 
intestinal juice to the pancreatic duct, mechanical injury of the pancreatic duct caused by the 
deep cannulation of a catheter and related devices including a guidewire, hydrostatic injury 
from the rise of pressure in the pancreatic duct due to repeated pancreatography with 
contrast agents, or the infusion of water or saline solution in manometry and pancreatic 
scope procedures, and thermal injury of the pancreas causing papillary edema due to 
radiofrequency ablation (Table 1). One of the most likely mechanisms is impaired drainage 
from the pancreatic duct caused by papillary edema or spasm of the sphincter of Oddi after 
ERCP procedures (10-14,19,22,25). Another is local injury of the papilla and pancreatic duct 
as a result of ERCP procedures, or forceful and repetitive contrast injections causing local 
inflammation (1-20,26). This may lead to premature intracellular activation of proteolytic 
enzymes, consequently causing further damage and local inflammation as indicated by 
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increased levels of cytokines, and possible initiation of a systemic inflammatory response 
with multi-organ involvement (1,10,11,13). 
 
Table 1. Suggested mechanisms of post-ERCP pancreatitis 
3. Risk factors of post-ERCP pancreatitis 
PEP can be prevented by careful patient selection with full consideration of the risk factors 
for PEP. Previous researchers have reported several factors which may increase the risk of 
PEP (1-27). A meta-analysis of 15 prospective cohort studies and 52 retrospective cohort 
studies previously evaluated and elucidated the risk factors of PEP.  
Freeman et al. (1,2) reported that the high risks of PEP were associated with both patient-
related risk factors and procedure-related risk factors on multivariate analysis of prospective 
studies and meta-analyses (Table 2). In their review, they advocated special caution in 
performing ERCP-related procedures in patients with specific patient-related risk factors 
(e.g., young age, female gender, suspected sphincter of Oddi dysfunction (SOD), prior PEP, 
recurrent pancreatitis, and absence of chronic pancreatitis) and procedure-related risk 
factors (e.g., pancreatic duct injection, pancreatic sphincterotomy, balloon dilation of an 
intact biliary sphincter, difficult or failed cannulation, and pre-cut (access) sphincterotomy).  
 
Table 2. Risk factotrs of post-ERCP pancreatitis on multivariate analysis 
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Cheng et al. (3) also reported the risk factors of PEP in a large prospective multivariate 
analysis as patient-related risk factors (e.g., suspected SOD, a history of PEP, and young age 
(< 60 yrs)) and procedure-related risk factors (e.g., previous minor papilla sphincterotomy, 
pancreatic duct injections of 2 or more, and trainee involvement).  
We previously (28) identified the risk factors of PEP on multivariate analysis as procedure-
related risk factors such as initial pancreatography, non-placement of a pancreatic stent (PS) 
after ERCP procedures, procedure time of 30 min or more, pancreatic-tissue sampling by 
any method, pancreatic-intraductal ultrasonography (IDUS), and difficulty of cannulation (≥ 
15 min). Moreover, we evaluated the correlation between the number of risk factors and 
PEP. We found a statistically significant association between PEP and the number of risk 
factors (P = 0.011), and the frequency of PEP was statistically significant when there were 
more than 3 risk factors (P = 0.001).  
Special consideration should be taken for risk factors, as indicated by multivariate analysis 
and meta-analysis, in performing ERCP-related procedures, although these procedures also 
involve comparatively wide-ranging variables such as the experience of the endoscopist. 
4. Prevention attempts 
To date, there have been several attempts to prevent PEP in terms of patient selection 
considering the risk factors of PEP, pharmacological drug administration and endoscopic 
procedures.  
4.1 Pharmacological prophylaxis 
Chemoprophylaxis to reduce the synthesis and secretion of proteolytic enzymes (octreotide 
or somatostatin), protease inhibitors (gabexate mesilate, ulinastatin, nafamostat, or 
aprotinin), antibiotics, and nonsteroidal anti-inflammatory drugs (NSAIDs) have been used 
to prevent PEP (1,29-42) (Table 3). Numerous randomized controlled trials (RCTs) and 
several meta-analyses have been performed to evaluate the efficacy of pharmacological 
drugs for preventing PEP. Freeman et al. evaluated and reviewed the results of previous 
studies (1), and found that most of these studies failed to show clearly the efficacy of 
pharmacological drugs, although some promising drugs for preventing PEP were indicated. 
However, their results should be interpreted in consideration of a lack of unified study 
design, for example, the selection of high-risk cases, mixed high-risk and non-high-risk 
cases, and a variety of criteria to define PEP. The outcomes varied and there is as yet no 
consensus on whether or not chemoprophylaxis is useful for preventing PEP.  
4.1.1 Gabexate mesilate 
Andriulli et al. (29) demonstrated that gabexate mesilate was effective for PEP evaluation. 
However, they found that the prophylactic use of gabexate mesilate did not prevent ERCP-
related pancreatic damage, even in patients at high risk for PEP in an additional study of the 
same subject group. Four other meta-analyses (29-32) of RCTs clearly showed that gabexate 
mesilate was ineffective in preventing PEP, (odds ratio [OR], 0.67; 95% confidence interval 
[CI], 0.31 – 1.47) and that it was not useful in preventing severe pancreatitis, death, 
hyperamylasemia, or abdominal pain (30). On the other hand, another meta-analysis which 
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considered the administration schedule (31) showed that the incidence of PEP after long-
term infusion (12 h) of gabexate mesilate was significantly decreased by 5.2% (95% CI, 1.1 – 
9.4, P = 0.01), although an examination of short-term infusion (within 12 h) failed to show its 
usefulness in PEP.  
 
Table 3. Pharmacologocal interventions to reduce risk of post-ERCP pancreatitis 
4.1.2 Ulinastatin 
Tsujino et al. (33) in their multicenter RCT showed that ulinastatin significantly lowered the 
incidence of PEP in the ulinastatin-administered group compared with the control group (2.9% 
vs. 7.4%, P = 0.041). Another RCT, which compared a group given a high dosage of ulinastatin 
(450,000 U) with a group given a low dosage of ulinastatin (150,000 U) and a group 
administered gabexate mesilate (900 mg) showed PEP rates of 6.5%, 8.5%, and 4.3%, 
respectively, indicating no significant differences among the groups (34). Ueki et al. conducted 
a RCT which compared a group given ulinastatin (150,000 units) and a group given gabexate 
mesilate (600 mg) and demonstrated a similar PEP rate in both groups, indicating no 
difference between the 2 groups (35). Chen at al. in their meta-analysis (36) showed that the 
incidence of PEP was significantly reduced by ulinastatin (OR, 0.53; 95% CI, 0.31 - 0.89; P = 
0.02), as well as the incidence of hyperamylasemia (OR, 0.42; 95% CI, 0.30 - 0.59; P < 0.00001); 
however, subsequent sensitivity and subgroup analyses produced conflicting results. The 
authors concluded that ulinastatin had value in preventing PEP in average-risk patients when 
administered intravenously at a dose of at least 150,000 U, given immediately before ERCP.  
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4.1.3 Somatostatin and octreotide 
A meta-analysis (32) of 9 RCTs showed a PEP rate of 7.3% in control groups and 5.3% in the 
groups administered somatostatin and octreotide (OR, 0.73, 95% CI, 0.54 – 1.006; relative 
risk [RR], 0.734, 95% CI, 0.535 – 1.006), indicating no significant difference between the 2 
groups. In contrast, a different meta-analysis (31) showed that in terms of the administration 
schedule of somatostatin, long-term infusion (12 h) was associated with a decrease in PEP 
rate by 7.7% (95% CI, 3.4 – 12.0; P < 0.0001). Short-term infusion (within 12 h) of 
somatostatin failed to show usefulness in preventing PEP. A study with bolus injections 
revealed that a bolus injection of somatostatin significantly reduced the PEP rate by 8.2% 
(95% CI, 4.4 – 12.0; P < 0.0001). A meta-analysis of the bolus injection groups in 3 other RCTs 
showed that a bolus injection of somatostatin was useful in preventing PEP (OR, 0.271, 95% 
CI, 0.138 – 0.536; difference in incidence 8.2%, 95% CI, 4.4 – 12.0; number needed to treat 
[NNT] = 12, 95% CI, 8 – 23).  
A meta-analysis of 15 RCTs involving octreotide demonstrated that the overall examination 
of 2,621 cases failed to show the usefulness of octreotide in preventing PEP (OR, 0.78; 95% 
CI, 0.57 – 1.08) (38). However, when the analysis was limited to a total of 1,714 cases 
including the cases in 5 RCTs in which more than 200 cases were studied, it was shown that 
the PEP rate was significantly decreased by octreotide (OR, 0.50; 95% CI, 0.32 – 0.79; P = 
0.003; NNT, 31). 
4.1.4 Nonsteroidal anti-inflammatory drugs 
A meta-analysis of 6 RCTs involving the administration of NSAIDs showed that the PEP 
rate was significantly lower in the NSAID-administered group (8.9% vs. 16.8%; OR, 0.46; 
95% CI, 0.32 – 0.65; P < 0.0001) (39). Of these 6 RCTs, a meta-analysis of 4 RCTs evaluating a 
rectally administered drug showed that the single use of NSAIDs just before or after ERCP 
was useful in preventing PEP (4.4% vs. 12.5%; RR, 0.36; 95% CI, 0.22 – 0.60; NNT, 15) (40). A 
subgroup analysis of the same 4 RCTs demonstrated that in the NSAID-administered group, 
there was a significant decrease in the PEP rate in both the low-risk group (RR, 0.29; 95% CI, 
0.12 – 0.71; P = 0.006) and the high-risk group (RR, 0.40; 95% CI, 0.23 – 0.72; P = 0.002) (41). 
Allopurinol, steroids, N-acetylcysteine, and mitogen-activated protein kinase inhibitors all 
failed to show a significant preventative effect in PEP (42). 
4.1.5 Endoscopic procedures 
Careful pancreatic duct injection and avoiding cannulation trauma are essential in 
performing ERCP-related procedures. Moreover, the placement of a PS with internal and 
external flanges, or a nasopancreatic drainage tube (9,10) has been performed. To prevent 
PEP, some endoscopists have inserted a naso-pancreatic drainage tube into the pancreatic 
duct (9,10) or employed a flanged PS, apparently not considering the possible advantages of 
spontaneous dislodgement (10-14,19,20). A temporary PS has recently become commercially 
available and has been reported to be effective in preventing PEP (1,15,17-20,25). PSs are 
classified into those with and without flanges on the pancreatic ductal side. The former is 
unlikely to naturally dislodge, and endoscopic removal is often necessary. As for the latter 
unflanged PS, the rate of natural dislodgement within a short period is high (1,17,25), and 
re-insertion of an endoscope for removal is generally unnecessary.  
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Several, mainly non-prospective, randomized studies (9-12,14,18-21) have evaluated 
endoscopic drainage using a PS with flanges on both sides, unlike our pancreatic duct 
spontaneous dislodgement stent (PSDS), for preventing PEP in high-risk patients (Table 4). 
The results suggested that the frequency of PEP decreased, and the PS provided a 
maintained drainage route when the papilla was blocked as a result of edema, or spasm of 
the sphincter of Oddi, or both, after the procedure.  
Recently, Freeman et al. (17) found that the insertion of a PS in high-risk patients reduced 
the frequency of PEP by 4 - 23%. In contrast, Smithline et al. (12) reported that PS insertion 
did not confer a significant beneficial effect in patients with previous biliary 
sphincterotomy.  
Sofuni et al. conducted 3 RCTs (15,28,43) to prospectively evaluate the usefulness of PSDS 
for PEP prophylaxis. In a preliminary single-center RCT (15), they evaluated PEP 
prophylaxis using the same unflanged 5-Fr PSDS in 80 consecutive patients, including those 
who underwent simple ERCP and those who received additional manipulation of the 
papilla through several stressful examinations including manometry, IDUS, and aspiration 
of pure pancreatic juice (PPJ). The trial revealed that a temporary unflanged 5-Fr PS reduced 
the frequency of PEP.  
 
Table 4. Studies of pancreatic atent for prevention of post-ERCP pancreatitis  
A multi-center RCT (43) of 6 endoscopy units based on a previous study (15) demonstrated 
that the insertion of PSDS significantly reduced the frequency of PEP (3.2% vs. 13.6%, P 
=0.019). In particular, in cases of hyperamylasemia, the placement of a PSDS significantly 
reduced the mean serum amylase level (767 vs. 1364 IU/l). This previous study clearly 
showed the efficacy of PSDS in preventing PEP.  
Finally, another RCT (28) conducted in 37 large endoscopic units evaluated whether or not 
the placement of a PSDS would prevent pancreatitis after ERCP-related procedures in 
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patients with any of the risk factors for PEP, as well as identified risk factors for PEP. The 
results demonstrated that the placement of a PSDS significantly reduced the frequency of 
PEP in the analysis, excluding invalid cases (7.9% vs. 15.2%, P = 0.021). A total of 6 risk 
factors for PEP were identified. 
Four meta-analyses (13,44-46) for prophylactic PS placement and PEP indicated that 
prophylactic temporary stent placement significantly reduces the risk of PEP.  
A meta-analysis by Andriulli et al. (44) showed that PEP developed in 16.5% of controls, and 
in 5.1% or 9.6% of the stent group on per-protocol (PP) or intention-to-treat (ITT) analyses. 
Analysis of 4 RCTs showed that PEP developed in 24.1% of controls, and in 6.1% or 12.0% of 
the stented patients on PP or ITT analyses. The risk was significantly lower in the stent 
group than in the controls (OR, 0.44; 95% CI, 0.24 - 0.81). The ORs for mild to moderate PEP 
were reduced in the stent group (OR, 0.537; 95% CI, 0.283 - 1.021), as well as those for severe 
PEP (OR, 0.123; 95% CI, 0.021 - 0.726). These trials indicated the benefits of pancreatic 
stenting in the prophylaxis of PEP; however, further randomized studies are needed before 
endorsing the routine use of this endoscopic procedure. 
Choudhary et al. (45) have recently found that PS placement decreases the risk of PEP and 
hyperamylasemia in high-risk patients. They concluded in a meta-analysis of RCTs that 
prophylactic PS placement decreased the odds of PEP (OR, 0.22; 95% CI, 0.12 - 0.38; P < 
0.01). Stents also decreased the level of hyperamylasemia (weighted mean difference, -
309.22; 95% CI, -350.95 to -267.49; P ≤ 0.01). Similar findings were also noted in other non-
randomized studies.  
Mazaki et al. (46) in their meta-analysis showed that PS placement after ERCP reduces the 
risk of PEP. They concluded that PS placement was associated with a statistically significant 
reduction in PEP (RR, 0.32; 95% CI, 0.19 - 0.52; P < 0.001). Subgroup analysis with 
stratification according to PEP severity showed that pancreatic stenting was beneficial in 
patients with mild to moderate PEP (RR, 0.36; 95% CI, 0.22 - 0.60; p < 0.001) and in patients 
with severe PEP (RR, 0.23; 95 % CI, 0.06 - 0.91; P = 0.04). Subgroup analysis according to 
patient selection demonstrated that pancreatic stenting was effective for both high-risk and 
mixed-case groups.  
Freeman et al. (1,20) also reported that unsuccessful cases of stent placement were at higher 
risk of PEP. Therefore, the PS insertion method for such risk factor cases, and for those in 
which cannulation is difficult should involve only the insertion of a guidewire before the 
main procedure. Moreover, it is occasionally difficult to place a stent in anatomic deformity 
cases. In such cases, the careful use of the Radifocus R  (Termo, Tokyo, Japan) guidewire or 
a 0.025-inch guidewire will enable successful stent placement. Taken together, PS placement 
is a strategy for preventing PEP which has been shown to be the most effective procedure 
related to prevention of PEP. 
Recently, to increase the success rate of primary deep biliary cannulation and reduce the risk 
of PEP, a wire-guided cannulation method has been proposed. However, several 
prospective studies (50-52) provided conflicting results as to whether the wire-guided 
cannulation technique reduces PEP risk compared with the standard method. Further RCTs 
are needed to confirm the effectiveness of this method. 
www.intechopen.com
 
Pancreatitis – Treatment and Complications 
 
80
4.1.6 Type of stent 
Stents with various diameters (3 - 7-Fr), lengths (2.0 - 12 cm), and with or without flanges 
have been used in previous studies of PEP. However, the optimal stent has not been 
determined (25,53).  
An internal flange is likely to make spontaneous PS dislodgment difficult, and in such cases, 
generally, the PS has to be removed 7 - 14 days after placement by additional endoscopy, 
which may not only injure the pancreatic duct, but also be an economic burden. An 
unflanged stent designed to pass spontaneously from the pancreatic duct may obviate the 
need for a second endoscopic procedure for stent retrieval. It may also reduce the overall 
cost of treatment and procedures, and the pancreatic duct is less likely to be injured by an 
internal flange when the PS dislodges spontaneously. It has been reported that 86% of 3-Fr 
stents spontaneously dislodged (25).  
Unflanged duodenal pigtail- and straight-type stents may spontaneously dislodge into the 
duodenum owing to pancreatic juice flow or friction with passing food. According to 
previous RCTs (15,43), unflanged duodenal pigtail- and straight-type stents spontaneously 
dislodge at a higher rate. The spontaneous dislodgement rates were 93.8% and 95.7%, and 
the durations until dislodgement were 2.7 and 2 days on average, respectively. The straight 
type of PS shape on the duodenal side is an important feature facilitating stent placement. 
Although the unflanged pigtail-type stent may be spontaneously dislodged at a higher rate 
due to friction with passing food and duodenal peristalsis, the handling of the short 
duodenal pigtail-type stent is slightly complicated, for example, the possible sudden 
forward movement of the stent on release, thus it requires close attention and experience. 
The straight-type PS with a flange on the duodenal side is easier to place than the pigtail-
type PS. 
Long-term PS retention is a significant risk factor with respect to chronic pancreatitis (1,25-
28). Rashdan et al. (25) reported that 3 - 4-Fr stents are more effective than traditionally used 
stents for preventing PEP, and that 5 - 6-Fr stents cause more significant stent-induced 
pancreatic duct changes than 3 - 4-Fr stents. However, 3 - 4-Fr stents require a small-caliber 
guidewire (0.018 - 0.025 inches), and the use of a small-caliber guidewire is difficult and 
requires a high level of experience (1,25-27). In contrast, the 0.035-inch guidewire used with 
the 5-Fr PS is relatively easy to use for stent placement.  
5. Conclusion 
PEP is the most common and potentially serious complication of ERCP-related procedures. 
The current optimal strategy for preventing PEP is considered to include the elucidation of 
its underlying mechanisms, identification of risk factors, administration of pharmacological 
drugs, and endoscopic procedures such as pancreatic stenting. The placement of a PS 
currently remains the most effective strategy for preventing PEP. 
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